Education
About Us
Working with TipRanks
Follow Us
Yield10 Bioscience (YTENQ)
OTHER OTC:YTENQ
RESEARCH TOOLSreports
Top Page
Yield10 Bioscience
(OTC:YTENQ)
Rating:23Underperform
Price Target:―
Yield10 Bioscience (YTENQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$69.00
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-1.47
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees29
SectorBasic Materials
Sector Strength56
IndustryAgriculture
Share Statistics
EPS (TTM)N/A
Shares Outstanding692,683
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Yield10 Bioscience Business Overview & Revenue Model
Company DescriptionYield10 Bioscience, Inc. (NASDAQ: YTEN) is an agricultural bioscience company focused on developing superior seed traits for the agriculture and food industries. Headquartered in Woburn, Massachusetts, Yield10 leverages its proprietary technology platforms to design and develop innovations aimed at enhancing crop productivity and sustainability. The company primarily operates within the biotechnology sector, emphasizing the development of novel traits for oilseed crops such as camelina, which can be used for producing renewable fuels and other valuable products.
How the Company Makes MoneyYield10 Bioscience generates revenue through collaborations and research agreements with agricultural and biotechnology companies interested in leveraging its advanced trait development technologies. The company sells licenses to its proprietary seed traits, enabling partner firms to integrate these innovations into their own crop production processes. Yield10 also engages in government and private grants to fund its research and development activities. Additionally, the company may earn revenue from the sale of seed products developed from its proprietary traits, although this is a developing area in its business model. Strategic partnerships and alliances with industry leaders play a significant role in enhancing its revenue streams and expanding its market reach.
Yield10 Bioscience Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q4-2023)
| % Change Since: 0.00%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call presented a balanced view with significant progress in regulatory approvals and strategic partnerships for omega-3 products, contrasted by challenges related to cash flow, continuing net losses, and the shift away from biofuels due to market uncertainties.Q4-2023 Updates
Positive Updates
USDA-APHIS and US EPA Approvals
Yield10 Bioscience received USDA-APHIS regulatory approval for growing HT Camelina and expects U.S. EPA approval for adding Camelina to its commercial herbicide label soon, enabling large-scale planting.
Omega-3 Product Milestones
Yield10 achieved regulatory approval for growth of omega-3 Camelina traits ahead of schedule and plans to commercialize omega-3 products by 2025-2026, aiming for $150 million to $300 million in revenue from 150,000 to 300,000 acres.
Strategic Partnerships and Licensing
Yield10 signed its first license agreement with Vision Bioenergy Oilseeds, majority-owned by Shell Oil, to scale up HT Camelina production and provide R&D services, securing $3 million in payments.
Camelina Oil Value Chain Establishment
Successfully demonstrated closed-loop production of Camelina oil, contracting over 1,200 acres of winter Camelina, and engaged growers for spring Camelina planting.
Negative Updates
Cash Position and Funding Needs
The company ended Q4 2023 with $1.1 million in cash, requiring additional funds soon to continue operations, with expected support only into Q2 2024.
Net Loss and Operating Expenses
Reported a net loss of $3.3 million for Q4 2023, similar to Q4 2022, and a full year net loss of $14.5 million, slightly higher than the $13.6 million loss in 2022.
Biofuel Market Uncertainty
Transitioned focus from biofuels to omega-3 due to regulatory uncertainties and surplus of soybean oil, impacting discussions with companies like Marathon Petroleum and Mitsubishi.
Company Guidance
During Yield10 Bioscience's Q4 2023 earnings call, the guidance focused on commercializing omega-3 products derived from Camelina seed oil. The company outlined its strategy to deliver omega-3 product samples and file for regulatory approval in Chile in 2024, targeting aquafeed, pet food, and other markets. Revenue projections estimate a potential of $150 million to $300 million from scaling production to 150,000 to 300,000 acres over the next five years. Yield10 also anticipates generating significant licensing revenue from its Camelina technologies, with a focus on R&D services to third parties for biofuel applications. Financially, the company ended 2023 with $1.1 million in cash, reporting a net loss of $14.5 million for the year, and expects its cash to support operations into Q2 2024, with ongoing efforts to secure additional funding.Yield10 Bioscience Financial Statement Overview
Summary
Yield10 Bioscience is facing severe financial challenges. It struggles with revenue generation and profitability, has a highly leveraged balance sheet, and suffers from negative cash flows, indicating significant operational and strategic risks.Income Statement
Yield10 Bioscience shows a declining revenue trend with significant losses over the years. Gross profit has improved in recent years, but EBIT and net income remain negative, indicating ongoing operational challenges. The company registered a substantial revenue decrease in the latest year, reflecting instability in income generation.25
Negative
Balance Sheet
The balance sheet reflects high leverage with a negative stockholders' equity in the latest report, indicating financial distress. The debt-to-equity ratio is unfavorable, and return on equity is negative due to consistent losses. The equity ratio has significantly worsened, showing potential solvency risks.15
Very Negative
Cash Flow
Cash flow analysis reveals persistent negative operating and free cash flows, highlighting liquidity issues. The free cash flow has worsened over the years, and the operating cash flow to net income ratio is unfavorable, emphasizing cash generation challenges.20
Very Negative
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 60.00K | -7.30M | 6.82M | 6.16M | -4.04M |
| EBITDA | -14.16M | -13.15M | -11.47M | -9.43M | -13.01M |
| Net Income | -14.46M | -13.57M | -11.03M | -10.21M | -12.96M |
Balance Sheet | |||||
| Total Assets | 3.91M | 8.09M | 20.41M | 14.52M | 16.72M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 3.18M | 2.65M | 3.17M | 3.62M | 4.22M |
| Total Liabilities | 6.39M | 3.69M | 4.39M | 4.99M | 5.83M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -10.11M | -11.56M | -9.44M | -8.72M | -8.71M |
| Operating Cash Flow | -10.07M | -11.40M | -9.25M | -8.66M | -8.65M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Yield10 Bioscience Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.03
Negative
0.39
Negative
Market Momentum
>-0.01
Negative
28.42
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YTENQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 28.42 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for YTENQ.
Yield10 Bioscience Risk Analysis
Yield10 Bioscience disclosed 43 risk factors in its most recent earnings report. Yield10 Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Yield10 Bioscience Peers Comparison
Overall Rating
UnderperformOutperform
Sector (43)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $188.13M | 193.48 | -3.00% | ― | -13.98% | -403.56% | |
58 Neutral | $435.31M | ― | -11.71% | ― | 341.75% | 20.16% | |
52 Neutral | $90.95M | ― | -54.21% | ― | -19.44% | -492.39% | |
51 Neutral | $15.60M | ― | -97.80% | ― | 70.25% | 66.22% | |
43 Neutral | C$927.89M | -8.64 | -0.02% | 2.70% | 23.29% | -43.30% | |
35 Underperform | $339.35K | ― | 366.81% | ― | -30.19% | 97.74% | |
23 Underperform | $69.00 | ― | 582.16% | ― | ― | ― |
* Basic Materials Sector Average
Performance Comparison
YTENQ
Yield10 Bioscience
0.02
-1.48
-98.67%
GEVO
Gevo
1.59
0.81
103.85%
TTOO
T2 Biosystems
0.01
-3.42
-99.71%
CRVO
CervoMed
9.15
-7.02
-43.41%
BIOX
Bioceres Crop Solutions
2.70
-7.42
-73.32%
AIMD
Ainos
3.34
0.19
6.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.